# ARROS-1 (NCT05118789)

> A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05118789
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Nuvalent Inc.
- Conditions: Locally Advanced Solid Tumor; Metastatic Solid Tumor
- Interventions: Zidesamtinib (NVL-520)
- Enrollment: 359
- Primary outcome: Maximum Tolerated Dose (MTD) (Phase 1)
- Primary outcome: Recommended Phase 2 Dose (RP2D)
- Primary outcome: Objective Response Rate (ORR) (Phase 2)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 6
- Podcasts: 6
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=arros-1-nct05118789

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05118789", "email": "<work email>"}; the inbox owner confirms by the emailed link.